American Journal of Kidney Diseases
Volume 56, Issue 3 , Pages 496-505 , September 2010

Association of Serum Phosphorus With Left Ventricular Mass in Men and Women With Stable Cardiovascular Disease: Data From the Heart and Soul Study

  • Georges Saab, MD

      Affiliations

    • Harry S. Truman Veterans Affairs Hospital, Columbia, MO
    • Department of Medicine, Washington University School of Medicine, Saint Louis, MO
    • ,
  • Mary A. Whooley, MD

      Affiliations

    • Department of Medicine, University of California San Francisco, San Francisco, CA
    • General Internal Medicine Section, Veterans Affairs Medical Center, San Francisco, CA
    • ,
  • Nelson B. Schiller, MD

      Affiliations

    • Department of Medicine, University of California San Francisco, San Francisco, CA
    • ,
  • Joachim H. Ix, MD, MAS

      Affiliations

    • Division of Nephrology, Department of Medicine, University of California San Diego, San Diego, CA
    • Nephrology Section, Veterans Affairs San Diego Healthcare System, University of California San Diego, San Diego, CA
    • Division of Preventive Medicine, Department of Family and Preventive Medicine, University of California San Diego, San Diego, CA
    • Corresponding Author InformationAddress correspondence to Joachim H. Ix, MD, MAS, Division of Nephrology, Department of Medicine, University of California San Diego, and San Diego VA Healthcare System, 3350 La Jolla Village Dr, Mail Code 9111-H, San Diego, CA 92161

Received 22 December 2009 ,Accepted 24 March 2010.

References 

  1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–617
  2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218
  3. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167(9):879–885
  4. Onufrak SJ, Bellasi A, Cardarelli F, et al. Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality. Am J Epidemiol. 2009;169(1):67–77
  5. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112(17):2627–2633
  6. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10–E17
  7. Adeney KL, Siscovick D, Ix JH, et al. Association of serum phosphate concentrations with vascular and valvular calcification in moderate chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. J Am Soc Nephrol. 2009;20:381–387
  8. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–1483
  9. Tuttle KR, Short RA. Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function. Clin J Am Soc Nephrol. 2009;4(12):1968–1973
  10. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009;20(2):397–404
  11. Ix JH, De Boer IH, Peralta CA, et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol. 2009;4(3):609–615
  12. Amann K, Toernig J, Kugel B, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003;4(63):1296–1301
  13. Neves K, Graciolli F, dos Reis L, Pasqualucci C, Moysés R, Jorgetti V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int. 2004;6(66):2237–2244
  14. Strózecki P, Adamowicz A, Nartowicz E, Odrowaz-Sypniewska G, Włodarczyk Z, Manitius J. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail. 2001;1(23):115–126
  15. Onufrak SJ, Bellasi A, Shaw LJ, et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis. 2008;199(2):424–431
  16. de Boer IH, Rue TC, Kestenbaum B. Serum phosphorus concentrations in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2009;53(3):399–407
  17. Faroqui S, Levi M, Soleimani M, Amlal H. Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. Kidney Int. 2008;73(10):1141–1150
  18. Cirillo M, Ciacci C, De Santo NG. Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults. N Engl J Med. 2008;359(8):864–866
  19. Meng J, Ohlsson C, Laughlin GA, et al. Sex hormones and serum phosphorus in older men: the Osteoporotic Fractures in Men (MrOs) Study. Kidney Int, in press.
  20. Ruo B, Rumsfeld J, Hlatky M, Liu H, Browner W, Whooley M. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA. 2003;2(290):215–221
  21. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Fetuin-A and kidney function in persons with coronary artery disease—data from the Heart and Soul Study. Nephrol Dial Transplant. 2006;21(8):2144–2151
  22. Lang R, Bierig M, Devereux R, et al. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;12(18):1440–1463
  23. Turakhia M, Schiller N, Whooley M. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol. 2008;(102):1131–1135
  24. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006;113(14):1760–1767
  25. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(2):173–179
  26. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51(3):395–406
  27. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol. 2005;16(5):1404–1412
  28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130(6):461–470
  29. DuBois D, DuBios EF. A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med. 1916;17:863–871
  30. Anan F, Yonemochi H, Masaki T, et al. High-density lipoprotein cholesterol and insulin resistance are independent and additive markers of left ventricular hypertrophy in essential hypertension. Hypertens Res. 2007;2(30):125–131
  31. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. C-Reactive protein, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertens Res. 2007;12(30):1177–1185
  32. Moran A, Katz R, Jenny N, et al. Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2008;52(5):839–848
  33. Smebye M, Iversen E, Høieggen A, et al. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE Study). Am J Cardiol. 2007;5(100):855–859
  34. Krailo MD, Pike MC. Estimation of the distribution of age at natural menopause from prevalence data. Am J Epidemiol. 1983;117(3):356–361
  35. Castelo-Branco C, Martínez de Osaba M, Pons F, González-Merlo J. The effect of hormone replacement therapy on postmenopausal bone loss. Eur J Obstet Gynecol Reprod Biol. 1992;2(44):131–136
  36. Stock JL, Coderre JA, Mallette LE. Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab. 1985;61(4):595–600
  37. Liel Y, Shany S, Smirnoff P, Schwartz B. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology. 1999;140(1):280–285
  38. Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, Fernandez-Martin JL, Naves-Diaz M, Cannata-Andia JB. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol. 2009;20(9):2009–2017

 Originally published online as doi:10.1053/j.ajkd.2010.03.030 on June 28, 2010.

PII: S0272-6386(10)00806-1

doi: 10.1053/j.ajkd.2010.03.030

American Journal of Kidney Diseases
Volume 56, Issue 3 , Pages 496-505 , September 2010

Article Tools

* Image Usage & Resolution